Cover Image
QR Code

Towards personalizing treatment strategies in mCRPC: can dual-tracer PET-CT provide insights into tumor biology, guide the optimal treatment sequence, and individualize decision-making (between chemotherapy, second-generation anti-androgens and PSMA-directed radioligand therapy) early in the disease course?

PSMA-directed radioligand therapy) early in the disease course? The therapeutic armamentarium of mCRPC has witnessed rapid evolution over the recent years, with a gamut of newly approved and "on-trial under clinical evaluation" therapies added to the traditional therapies including the cytotoxic che...

Full description

Published in:European Journal of Nuclear Medicine & Molecular Imaging Vol. 47; no. 8; pp. 1793 - 1798
Main Authors: Basu, Sandip, Parghane, Rahul V., Suman, Sonam, Joshi, Amit, Prabhash, Kumar, Bakshi, Ganesh, Banerjee, Sharmila
Format: Journal Article
Published: Springer Nature Jul2020
Online Access:View this record in EBSCOhost
Summary:PSMA-directed radioligand therapy) early in the disease course? The therapeutic armamentarium of mCRPC has witnessed rapid evolution over the recent years, with a gamut of newly approved and "on-trial under clinical evaluation" therapies added to the traditional therapies including the cytotoxic chemotherapy (taxanes) and immunotherapy (Sipuleucel-T) [[1]]. We have to mention here that [ SP 177 sp Lu]Lu-PSMA therapy, and also [ SP 68 sp Ga]Ga/[ SP 18 sp F]F-PSMA PET-CT imaging, though being now frequently adopted in advanced centres with such facilities, are still considered experimental in many of the European countries, the USA and other countries worldwide. Dual-tracer PET-CT in characterizing tumour biology of mCRPC: can this be employed for treatm... The concept of dual/multi-tracer PET-CT in studying and characterizing tumor biology can be considered an important development of recent years that has scientifically augmented the practice of precision oncology.